Rystiggo
Zilbrysq, A Complement C5 Inhibitor For Myasthenia Gravis, Gets FDA Approval As UCB’s Second Drug For The Rare Disease
Anika Sharma
UCB is celebrating an impressive streak of FDA approvals, securing the green light for both the plaque psoriasis treatment Bimzelx ...
UCB has achieved a long-awaited victory as the FDA grants approval for the myasthenia gravis drug Rystiggo
SG Tylor
Source – UCB On 27 June 2023, UCB faced regulatory challenges in the United States for the second consecutive year, ...
